Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
Stepinska
Janina
J
Banaszewski
Marek
M
Konopka
Anna
A
Szajewski
Tomasz
T
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D023921:Coronary Stenosis / Q000188:drug therapy / Q000628:therapy; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D005167:Factor VII / Q000235:genetics / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000627:therapeutic use; D015607:Stents; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D014654:Vascular Patency
D000925:Anticoagulants; D017984:Enoxaparin; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D014443:Tyrosine; D005167:Factor VII; D000077466:Tirofiban